कोशिश गोल्ड - मुक्त
Aptamers In Cancer Therapeutics
Express Pharma
|August 16-31, 2018
Dr Harleen Kaur, Senior Scientist, AstraZeneca USA, through her research paper, talks about collaborative approaches which can make huge difference in treating cancer.
-
Cancer is a disease caused by genetic mutation, which leads to uncontrolled proliferation of abnormal cells and their infiltration in normal tissues and organs of human body. Cancer is a global health problem and one of the leading causes of death worldwide including India. According to World Health Organization (WHO) reports, in 2015, cancer was responsible for 8.8 million deaths in 2015 with approximately 70 per cent cancer deaths occurring in low and middle-income countries. In India alone, cancer accounted for about 949,000 new cases and 634,000 deaths in 20081. Air pollution and smoking and chewing tobacco are the chief causes of cancer in India.
यह कहानी Express Pharma के August 16-31, 2018 संस्करण से ली गई है।
हजारों चुनिंदा प्रीमियम कहानियों और 10,000 से अधिक पत्रिकाओं और समाचार पत्रों तक पहुंचने के लिए मैगज़्टर गोल्ड की सदस्यता लें।
क्या आप पहले से ही ग्राहक हैं? साइन इन करें
Express Pharma से और कहानियाँ
Express Pharma
Speed and flexibility play a critical role in how we compete with larger global players
Kriti Jajoo, VP-BD and Strategy, Shriji Polymers, as the next-gen leader, speaks on how the company is evolving with a leadership approach that balances technology, sustainability, and customer-centricity to create long-term value, in an interview with Express Pharma
6 mins
January 2026
Express Pharma
Vizag rising: Shaping India's pharma future
At the Vizag Pharma Summit 2025, hosted by Express Pharma, industry leaders discussed how quality, R&D, compliance, and emerging technologies are driving India's next phase of pharma growth
9 mins
January 2026
Express Pharma
Future of pharma: Trends, challenges & AI
Industry experts discussed how Al is transforming pharmaceutical R&D, highlighting both the promise and the practical limitations of current technologies
2 mins
January 2026
Express Pharma
Gandhi Automations presents multi-composites, high-performance door PRIME NEO for clean environments
When it comes to pharmaceutical facilities and laboratories, clean rooms' hygiene and protection from environmental contamination are the most important factors to consider.
1 mins
January 2026
Express Pharma
Can Indian biosimilars and generics restate accessibility in global underserved markets?
Hari Kiran Chereddi, MD & CEO - HRV Pharma & NHG Pharma highlights that India's success in generics is no longer enough, as the world now demands advanced biologics, biosimilars, and personalised medicines. He further emphasises on the need for stronger regulation, innovation, and investment so India can lead in next-generation therapies and expand global access to cutting-edge healthcare
3 mins
January 2026
Express Pharma
The next wave of growth will belong not to the fastest manufacturers but to the most innovative problem-solvers
As India moves into 2026, industry experts state that the next phase of growth in pharmaceuticals will depend on strengthening formulation R&D, building a skilled and adaptable workforce, and closing gaps between academic research and industry needs.
6 mins
January 2026
Express Pharma
Results win customers. Leadership discipline keeps them
Drawing themes from his new book The Dual Mandate in B2B - Driving Results. Shaping Culture, Mohan Joshi - Global C-Suite Partner & Former President, SCHOTT India, discusses leadership systems, alignment, and execution in conversation with Neha Aathavale.
3 mins
January 2026
Express Pharma
INDIA'S INNOVATION JOURNEY FROM PROMISE TO PROOF
India's pharma ecosystem is ready to embrace stronger science and bolder ideas. Turning early breakthroughs into scalable, sustainable innovation remains the challenge
8 mins
January 2026
Express Pharma
PRUV® -The original Sodium Stearyl Fumarate
JRS Pharma's PRUV® is the original sodium stearyl fumarate (SSF) introduced in the market over 20 years ago
5 mins
January 2026
Express Pharma
Odisha's pharma pitch
The inaugural Odisha Pharma Summit 2025 delivered strong early signals of intent, positioning the state as an upcoming destination for PLI-triggered expansions, to complement existing pharma hubs. As Hemant Sharma, ACS Industry Dept and I&PR Dept, Govt of Odisha puts it, the aim is to “become a good, viable second option.” How fast can the eastern newcomer catch up and become India's next life sciences hub, asks Viveka Roychowdhury
5 mins
January 2026
Translate
Change font size
